tert-butyl ((3R,6S)-6-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)-methyl)tetrahydro-2H-pyran-3-yl)carbamate | 881657-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl ((3R,6S)-6-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)-methyl)tetrahydro-2H-pyran-3-yl)carbamate
• 英文别名: (3R,6S)-[6-(1-phenyl-1H-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester；tert-butyl N-[(3R,6S)-6-[(1-phenyltetrazol-5-yl)sulfonylmethyl]oxan-3-yl]carbamate
• CAS: 881657-49-4
• 化学式: C₁₈H₂₅N₅O₅S
• 分子量: 423.493
• InChiKey: GRCYJTGPLQQLOX-HIFRSBDPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  134
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  tert-butyl ((3R,6S)-6-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)-methyl)tetrahydro-2H-pyran-3-yl)carbamate 在 甲基磺酰胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 、 乙酸乙酯 、 叔丁醇 为溶剂， 反应 1.5h， 生成 (1S,2R)-1-[(2S,5R)-5-aminooxan-2-yl]-2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethane-1,2-diol
  参考文献：
  名称：

  Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity

  摘要：

  There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K channel block. On the other hand, analog 49e displayed lower hERG K channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.

  DOI：

  10.1021/jm400963y
• 作为产物：
  描述：

  (2S,5R)-5-[(tert-butoxycarbonyl)amino]-2-[(tert-butyldimethylsilanyloxy)methyl]-2,5-dihydro-6H-pyran 在 platinum(IV) oxide 4-二甲氨基吡啶 、 ammonium heptamolybdate 、 氢氧化钾 、 水 、 氢气 、 双氧水 、 溶剂黄146 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 为溶剂， 反应 40.0h， 生成 tert-butyl ((3R,6S)-6-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)-methyl)tetrahydro-2H-pyran-3-yl)carbamate
  参考文献：
  名称：

  WO2008/152603

  摘要：

  公开号：

文献信息

• Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram Positive Activity and Improved Safety Profile
  作者：Jean-Philippe Surivet、Cornelia Zumbrunn、Georg Rueedi、Daniel Bur、Thierry Bruyère、Hans Locher、Daniel Ritz、Peter Seiler、Christopher Kohl、Eric A. Ertel、Patrick Hess、Jean-Christophe Gauvin、Azely Mirre、Verena Kaegi、Marina Dos Santos、Stéphanie Kraemer、Mika Gaertner、Jonathan Delers、Michel Enderlin-Paput、Maria Weiss、Romain Sube、Hakim Hadana、Wolfgang Keck、Christian Hubschwerlen

  DOI：10.1021/jm501590q

  日期：2015.1.22

  that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. During the course of our optimization program, lead compound

  迫切需要能够有效抵抗由多重耐药性病原体引起的感染的新型抗菌药物。在以前的报告中，我们显示了细菌II型拓扑异构酶（DNA促旋酶和拓扑异构酶IV）的基于四氢吡喃的抑制剂表现出强大的抗菌活性，并且与氟喹诺酮类药物没有靶介导的交叉耐药性。在我们的优化计划过程中，先导化合物5由于心血管安全性研究中的不良发现，该药物被列为优先事项。为了减轻这些发现并进一步优化此类化合物的药理作用，我们确定了基于四氢吡喃的分子亚系列，这些分子为有效的DNA促旋酶和拓扑异构酶IV抑制剂，并且对革兰氏阳性病原体（包括临床上）表现出优异的抗菌活性相关抗性分离株。此类的代表化合物32d仅引起hERG K +通道和hNa V 1.5 Na +通道的弱抑制，并且在麻醉的豚鼠中未观察到对心血管参数的影响。在动物感染模型中的体内功效已被证明可抵抗金黄色葡萄球菌和肺炎链球菌菌株。
• [EN] 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES<br/>[FR] DÉRIVÉS DE 5-AMINO-2-(1-HYDROXYÉTHYL)TÉTRAHYDROPYRANE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010067332A1

  公开（公告）日：2010-06-17

  The invention relates to antibacterial compounds of formula I wherein R1 represents alkoxy (notably methoxy); R2 represents H or F; each of R3, R4, R5 and R6 represents independently H or D; V represents CH and W represents CH or N or V represents N and W represents CH; Y represents CH or N; Z represents O, S or CH2; and A represents CH2, CH2CH2 or CD2CD2; and salts of such compounds.

  该发明涉及公式I的抗菌化合物，其中R1代表烷氧基（特别是甲氧基）；R2代表H或F；R3、R4、R5和R6中的每一个独立地代表H或D；V代表CH，W代表CH或N，或者V代表N且W代表CH；Y代表CH或N；Z代表O、S或CH2；A代表CH2、CH2CH2或CD2CD2；以及这些化合物的盐。
• 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives
  申请人：Hubschwerlen Christian

  公开号：US20110245259A1

  公开（公告）日：2011-10-06

  The invention relates to antibacterial compounds of formula I wherein R 1 represents alkoxy (notably methoxy); R 2 represents H or F; each of R 3 , R 4 , R 5 and R 6 represents independently H or D; V represents CH and W represents CH or N, or V represents N and W represents CH; Y represents CH or N; Z represents O, S or CH 2 ; and A represents CH 2 , CH 2 CH 2 or CD 2 CD 2 ; and salts of such compounds.

  该发明涉及公式I的抗菌化合物，其中R1代表烷氧基（特别是甲氧基）；R2代表H或F；R3、R4、R5和R6中的每一个独立地代表H或D；V代表CH，W代表CH或N，或者V代表N，W代表CH；Y代表CH或N；Z代表O、S或CH2；A代表CH2、CH2CH2或CD2CD2；以及这些化合物的盐。
• 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
  申请人：Actelion Pharmaceuticals

  公开号：US08211890B2

  公开（公告）日：2012-07-03

  The invention relates to antibacterial compounds of formula I wherein R1 represents alkoxy (notably methoxy); R2 represents H or F; each of R3, R4, R5 and R6 represents independently H or D; V represents CH and W represents CH or N, or V represents N and W represents CH; Y represents CH or N; Z represents O, S or CH2; and A represents CH2, CH2CH2 or CD2CD2; and salts of such compounds.

  本发明涉及公式I的抗菌化合物，其中：R1代表烷氧基（特别是甲氧基）；R2代表氢或氟；R3、R4、R5和R6分别独立地代表氢或重氢（D）；V代表CH，W代表CH或N，或者V代表N，W代表CH；Y代表CH或N；Z代表O、S或CH2；A代表CH2、CH2CH2或CD2CD2；以及这些化合物的盐。
• 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES
  申请人：Hubschwerlen Christian

  公开号：US20100179135A1

  公开（公告）日：2010-07-15

  Antibacterial compounds including 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives are provided, and methods of treatment or prevention of bacterial infection with such compounds are provided.

  提供了包括3-氨基-6-(1-氨乙基)-四氢吡喃衍生物在内的抗菌化合物，并提供了使用这些化合物进行治疗或预防细菌感染的方法。